EVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM)
Eliem Therapeutics Inc (NASDAQ:ELYM), a company focused on developing therapies for pain, epilepsy, and depression, recently saw a significant insider transaction. Valerie Morisset, the Executive Vice President, Research & Development and Chief Scientific Officer, sold 50,000 shares of the company on July 16, 2024. The transaction was documented in an SEC Filing. Following this sale, the insider now owns 202,306 shares of Eliem Therapeutics Inc.
Over the past year, Valerie Morisset has sold a total of 310,650 shares and has not made any purchases of the company's stock. This recent transaction continues a trend of insider sales at Eliem Therapeutics Inc, with a total of 6 insider sells and only 1 insider buy over the past year.
Shares of Eliem Therapeutics Inc were trading at $7.13 on the day of the transaction. The company's market cap is currently $454.809 million. Investors often monitor insider transactions as they can provide insights into the company's performance and insiders' views on the stock's valuation.
For further analysis, here is the insider trend image showing the recent activities:
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This insider sale might be of interest to current and potential investors trying to understand the market sentiment and the financial health of Eliem Therapeutics Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.